Pengobatan Masa Depan dengan Farmakogenomik - Levana Sani | Endgame #26

TL;DR

Levana Sani discusses Nalagenetics' role in personalized medicine.

Transcript

Market size in healthcare almost means nothing. You know it's a big problem. Everybody knows it's a big problem. The question is, "Who holds the money? [Voiceover: This is Endgame] GITA WIRJAWAN: Hi friends, today we are having Levana Sani the founder of Nalagenetics. It is an honor to have her to talk about genetics. Levi, thanks for coming.... Read More

Key Insights

• Levana Sani's interest in biochemistry was sparked by her family's background in pharmacy and her education in science, leading her to genetics.
• Nalagenetics aims to improve drug efficacy by tailoring genetic tests to local populations, focusing on pharmacogenomics.
• The company collaborates with health agencies to reduce adverse drug reactions, notably in Indonesia, by using genetic screening to guide treatment.
• Nalagenetics faces challenges in integrating genetic testing into healthcare systems due to varying stakeholder interests and systemic issues.
• The company emphasizes the importance of localized genetic data to improve healthcare outcomes and reduce costs.
• Pharmacogenomics is seen as a crucial field for advancing personalized medicine, with potential to significantly reduce healthcare costs.
• Levana Sani believes in the importance of scientific education to increase acceptance and understanding of genetic testing among doctors and patients.
• The conversation around genetics is shifting towards preventive healthcare and wellness, with Nalagenetics aiming to be at the forefront of this change.

Questions & Answers

Q: What inspired Levana Sani to pursue a career in biochemistry and genetics?

Levana Sani's interest in biochemistry was influenced by her family's background in pharmacy and business. Her educational choices in science and exposure to discussions about drug efficacy and side effects at home fueled her curiosity about the molecular interactions in biochemistry and genetics.

Q: What is the mission of Nalagenetics?

Nalagenetics aims to improve drug efficacy and reduce adverse drug reactions by providing localized genetic tests tailored to the genetic makeup of specific populations. This approach ensures that clinical recommendations are appropriate for the target community, making pharmacogenomics a key focus for the company.

Q: How does Nalagenetics address the challenges in integrating genetic testing into healthcare?

Nalagenetics addresses these challenges by collaborating with healthcare stakeholders, including insurance companies and doctors, to demonstrate the cost-effectiveness and clinical benefits of genetic testing. The company also emphasizes the need for scientific education to increase acceptance among healthcare providers.

Q: What role does pharmacogenomics play in Nalagenetics' strategy?

Pharmacogenomics is central to Nalagenetics' strategy as it focuses on tailoring drug treatments based on individual genetic profiles. This approach reduces adverse drug reactions and improves efficacy, making it a promising field for personalized medicine and cost reduction in healthcare.

Q: What are some of the challenges faced by Nalagenetics in its operations?

Nalagenetics faces challenges such as systemic issues in healthcare, varying incentives among stakeholders, and the need for widespread acceptance of genetic testing. The company also contends with funding limitations and the complexity of integrating new technologies into existing healthcare frameworks.

Q: How does Nalagenetics plan to expand its impact in the healthcare industry?

Nalagenetics plans to expand its impact by focusing on localized genetic data to tailor healthcare solutions, collaborating with international partners, and leveraging technology to provide actionable insights. The company aims to scale its operations in Southeast Asia and beyond, emphasizing preventive healthcare and wellness.

Q: What is Levana Sani's view on the future of genetic testing in healthcare?

Levana Sani views genetic testing as a transformative tool in healthcare, with the potential to personalize medicine, reduce costs, and improve patient outcomes. She advocates for increased scientific education and stakeholder collaboration to realize the full benefits of genetic testing in preventive and personalized healthcare.

Q: What are the potential benefits of genetic testing according to Nalagenetics?

The potential benefits of genetic testing, as seen by Nalagenetics, include improved drug efficacy, reduced adverse reactions, and cost savings in healthcare. By tailoring treatments to individual genetic profiles, pharmacogenomics offers a pathway to more effective and personalized healthcare solutions.

Summary & Key Takeaways

• Levana Sani, founder of Nalagenetics, discusses her journey from a family background in pharmacy to establishing a biotech startup focused on pharmacogenomics in Indonesia and Asia.

• Nalagenetics aims to improve drug efficacy and reduce adverse reactions by localizing genetic tests to specific populations, working closely with healthcare agencies and insurance companies.

• The company faces challenges in integrating genetic testing into healthcare systems but remains optimistic about the potential of pharmacogenomics to revolutionize personalized medicine and reduce healthcare costs.